Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Laura Mauri, M.D.

Co-Author

This page shows the publications co-authored by Laura Mauri and Sharon-Lise Normand.
Connection Strength

3.195
  1. Mauri L, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, Zhou Z, Resnic FS, Normand SL. Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation. 2008 Oct 28; 118(18):1817-27.
    View in: PubMed
    Score: 0.444
  2. Mauri L, Silbaugh TS, Garg P, Wolf RE, Zelevinsky K, Lovett A, Varma MR, Zhou Z, Normand SL. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med. 2008 Sep 25; 359(13):1330-42.
    View in: PubMed
    Score: 0.443
  3. Mauri L, Normand SL. Studies of drug-eluting stents: to each his own? Circulation. 2008 Apr 22; 117(16):2047-50.
    View in: PubMed
    Score: 0.430
  4. Yeh RW, Mauri L, Wolf RE, Romm IK, Lovett A, Shahian D, Normand SL. Population trends in rates of coronary revascularization. JAMA Intern Med. 2015 Mar; 175(3):454-6.
    View in: PubMed
    Score: 0.173
  5. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014 Dec 04; 371(23):2155-66.
    View in: PubMed
    Score: 0.169
  6. Yeh RW, Czarny MJ, Normand SL, Kereiakes DJ, Holmes DR, Brindis RG, Weaver WD, Rumsfeld JS, Roe MT, Kim S, Driscoll-Shempp P, Mauri L. Evaluating the generalizability of a large streamlined cardiovascular trial: comparing hospitals and patients in the dual antiplatelet therapy study versus the National Cardiovascular Data Registry. Circ Cardiovasc Qual Outcomes. 2015 Jan; 8(1):96-102.
    View in: PubMed
    Score: 0.169
  7. Yeh RW, Vasaiwala S, Forman DE, Silbaugh TS, Zelevinski K, Lovett A, Normand SL, Mauri L. Instrumental variable analysis to compare effectiveness of stents in the extremely elderly. Circ Cardiovasc Qual Outcomes. 2014 Jan; 7(1):118-24.
    View in: PubMed
    Score: 0.158
  8. Matteau A, Yeh RW, Kereiakes D, Orav EJ, Massaro J, Steg PG, Normand SL, Cutlip DE, Mauri L. Frequency of the use of low- versus high-dose aspirin in dual antiplatelet therapy after percutaneous coronary intervention (from the Dual Antiplatelet Therapy study). Am J Cardiol. 2014 Apr 01; 113(7):1146-52.
    View in: PubMed
    Score: 0.158
  9. Jacobs AK, Normand SL, Mauri L. PCI at hospitals with or without on-site cardiac surgery. N Engl J Med. 2013 07 25; 369(4):392-3.
    View in: PubMed
    Score: 0.155
  10. Yeh RW, Rosenfield K, Zelevinsky K, Mauri L, Sakhuja R, Shivapour DM, Lovett A, Weiner BH, Jacobs AK, Normand SL. Sources of hospital variation in short-term readmission rates after percutaneous coronary intervention. Circ Cardiovasc Interv. 2012 Apr; 5(2):227-36.
    View in: PubMed
    Score: 0.141
  11. Mauri L, Normand SL, Pencina M, Cutlip DE, Jeon C, Dreyer P, Kuntz RE, Baim DS, Jacobs AK. Rationale and design of the MASS COMM trial: A randomized trial to compare percutaneous coronary intervention between MASSachusetts hospitals with cardiac surgery on-site and COMMunity hospitals without cardiac surgery on-site. Am Heart J. 2011 Nov; 162(5):826-31.
    View in: PubMed
    Score: 0.137
  12. Charytan DM, Varma MR, Silbaugh TS, Lovett AF, Normand SL, Mauri L. Long-term clinical outcomes following drug-eluting or bare-metal stent placement in patients with severely reduced GFR: Results of the Massachusetts Data Analysis Center (Mass-DAC) State Registry. Am J Kidney Dis. 2011 Feb; 57(2):202-11.
    View in: PubMed
    Score: 0.129
  13. Mauri L, Kereiakes DJ, Normand SL, Wiviott SD, Cohen DJ, Holmes DR, Bangalore S, Cutlip DE, Pencina M, Massaro JM. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J. 2010 Dec; 160(6):1035-41, 1041.e1.
    View in: PubMed
    Score: 0.129
  14. Garg P, Normand SL, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, Varma MR, Zhou Z, Mauri L. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry. Circulation. 2008 Nov 25; 118(22):2277-85, 7p following 2285.
    View in: PubMed
    Score: 0.112
  15. Wasfy JH, Strom JB, Waldo SW, O'Brien C, Wimmer NJ, Zai AH, Luttrell J, Spertus JA, Kennedy KF, Normand SL, Mauri L, Yeh RW. Clinical preventability of 30-day readmission after percutaneous coronary intervention. J Am Heart Assoc. 2014 Sep 26; 3(5):e001290.
    View in: PubMed
    Score: 0.042
  16. Wasfy JH, Strom JB, O'Brien C, Zai AH, Luttrell J, Kennedy KF, Spertus JA, Zelevinsky K, Normand SL, Mauri L, Yeh RW. Causes of short-term readmission after percutaneous coronary intervention. Circ Cardiovasc Interv. 2014 Feb; 7(1):97-103.
    View in: PubMed
    Score: 0.040
  17. Wasfy JH, Rosenfield K, Zelevinsky K, Sakhuja R, Lovett A, Spertus JA, Wimmer NJ, Mauri L, Normand SL, Yeh RW. A prediction model to identify patients at high risk for 30-day readmission after percutaneous coronary intervention. Circ Cardiovasc Qual Outcomes. 2013 Jul; 6(4):429-35.
    View in: PubMed
    Score: 0.038
  18. Jacobs AK, Normand SL, Massaro JM, Cutlip DE, Carrozza JP, Marks AD, Murphy N, Romm IK, Biondolillo M, Mauri L. Nonemergency PCI at hospitals with or without on-site cardiac surgery. N Engl J Med. 2013 Apr 18; 368(16):1498-508.
    View in: PubMed
    Score: 0.038
  19. Amin AP, Spertus JA, Cohen DJ, Chhatriwalla A, Kennedy KF, Vilain K, Salisbury AC, Venkitachalam L, Lai SM, Mauri L, Normand SL, Rumsfeld JS, Messenger JC, Yeh RW. Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Arch Intern Med. 2012 Aug 13; 172(15):1145-52.
    View in: PubMed
    Score: 0.036
  20. Yeh RW, Normand SL, Wolf RE, Jones PG, Ho KK, Cohen DJ, Cutlip DE, Mauri L, Kugelmass AD, Amin AP, Spertus JA. Predicting the restenosis benefit of drug-eluting versus bare metal stents in percutaneous coronary intervention. Circulation. 2011 Oct 04; 124(14):1557-64.
    View in: PubMed
    Score: 0.034
  21. Wang JC, Normand SL, Mauri L, Kuntz RE. Coronary artery spatial distribution of acute myocardial infarction occlusions. Circulation. 2004 Jul 20; 110(3):278-84.
    View in: PubMed
    Score: 0.021
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.